Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Genuine Parts Company (GPC) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Genuine Parts CompanyTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Genuine Parts Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.96 (market cap $29.60B), while Genuine Parts Company trades at $133.13 (market cap $18.62B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Genuine Parts Company pays a 3.15% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYGPC
Market Cap
$29.60B$18.62B
Sector
HealthConsumer Cyclical
52-Week High
$491.22$149.26
52-Week Low
$205.48$92.47
Enterprise Value
$27.56B$24.72B
Dividend Yield
3.15%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

Genuine Parts Company

GPC trades at $134.54, down 0.8% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings with EPS of $2.15 beating estimates of $2.08, while revenue grew 6% year-over-year to $6.5 billion. However, net income margin remains thin at 0.13% for 2025, though the P/S ratio of 0.75 suggests reasonable valuation relative to sales.

The stock offers a dividend yield supported by 70 years of increases, with analyst consensus target at $148.67 suggesting 10.5% upside. Key risks include compressed profit margins, rising debt levels, and sensitivity to automotive industry cycles. Institutional ownership shows mixed signals with some funds increasing positions while others trimmed holdings in Q1 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Genuine Parts Company

Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.

Read more on GPC